IN VITRO ANTICANCER ACTIVITY OF HISTATIN-1 COMBINATION WITH CISPLATIN IN HEAD AND NECK CANCER CELL LINES
Issued Date
2024-10-09
Resource Type
eISSN
23128852
Scopus ID
2-s2.0-85206123352
Pubmed ID
39396174
Journal Title
Experimental oncology
Volume
46
Issue
2
Start Page
101
End Page
109
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental oncology Vol.46 No.2 (2024) , 101-109
Suggested Citation
Jenwanichkul P., Amornphimoltham P. IN VITRO ANTICANCER ACTIVITY OF HISTATIN-1 COMBINATION WITH CISPLATIN IN HEAD AND NECK CANCER CELL LINES. Experimental oncology Vol.46 No.2 (2024) , 101-109. 109. doi:10.15407/exp-oncology.2024.02.101 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101655
Title
IN VITRO ANTICANCER ACTIVITY OF HISTATIN-1 COMBINATION WITH CISPLATIN IN HEAD AND NECK CANCER CELL LINES
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND: Chemotherapy of head and neck squamous cell carcinoma (HNSCC) is associated with significant side effects. Antimicrobial peptides (AMPs), which are naturally occurring defense molecules like defensin-1 and LL-37 found in human secretions, have demonstrated potential in prompting tumor cell apoptosis and enhancing the effect of chemotherapeutic agents. However, the anticancer potential of histatin has not yet been thoroughly examined. The aim of the study was to explore the anticancer activity of histatin, an AMP present in human saliva and used alone or in combination with cisplatin in HNSCC cell lines. MATERIALS AND METHODS: The gene expression of histatin was evaluated in the HSC4 and SCC25 cell lines by qRT-PCR. Cell proliferation was investigated at different concentrations of histatin peptide (His-1), cisplatin, and their combination using an MTT assay. RESULTS: SCC25 cells expressed both HTN1 (histatin-1) and HTN3 (histatin-3), whereas the HSC4 cell line expressed only HTN1. The combination of exogenous His-1 and cisplatin demonstrated a synergistic anti-proliferative effect against the HNSCC cell lines in a dosedependent manner. CONCLUSIONS: The combination of low-dose cisplatin and histatin inhibits HNSCC cell proliferation. His-1 sensitizes tumor cells to the cytotoxic effects of cisplatin potentially allowing for a reduction in its effective concentration.